...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
【24h】

RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.

机译:RPR 107393,一种有效的角鲨烯合酶抑制剂和口服有效的降胆固醇剂:与HMG-CoA还原酶抑制剂的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

Squalene synthase catalyzes the reductive dimerization of two molecules of farnesyl pyrophosphate to form squalene and is the first committed step in sterol synthesis. A specific inhibitor of squalene synthase would inhibit cholesterol biosynthesis but not prevent the formation of other products of the isoprenoid pathway, such as dolichol and ubiquinone. RPR 107393 [3-hydroxy-3-[4-(quinolin-6-yl)phenyl]-1-azabicyclo[2-2-2]octane dihydrochloride] and its R and S enantiomers are potent inhibitors of rat liver microsomal squalene synthase, with IC50 values of 0.6 to 0.9 nM. One hour after oral administration to rats, RPR 107393 inhibited de novo [14C]cholesterol biosynthesis from [14C]mevalonate in the liver with an ED50 value of 5 mg/kg. Diacid metabolites of [14C]farnesyl pyrophosphate were identified after acid treatment of the livers of these animals. These results support in vitro data demonstrating that these compounds are inhibitors of squalene synthase. In rats, RPR 107393 (30 mg/kg p.o. b.i.d. for 2 days) reduced total serum cholesterol by < or = 51%. In the same paradigm, the HMG-CoA reductase inhibitor lovastatin failed to lower serum cholesterol in rats. In marmosets, RPR 107393 (20 mg/kg b.i.d.) reduced plasma cholesterol concentration by 50% after 1 week of administration; this was greater than the reduction observed with lovastatin or pravastatin, neither of which produced > 31% reduction in plasma cholesterol when administered for 1 week at a dose of 50 mg/kg b.i.d. The R and S enantiomers of RPR 107393 (20 mg/kg p.o. q.d. for 7 days) reduced plasma low density lipoprotein cholesterol by 50% and 43%, respectively, whereas high density lipoprotein cholesterol was unchanged. In summary, RPR 107393 is a potent inhibitor of squalene synthase. It is an orally effective hypocholesterolemic agent in rats and marmosets that has greater efficacy than lovastatin or pravastatin in the marmoset.
机译:角鲨烯合酶催化两个分子的法呢基焦磷酸的还原性二聚化以形成角鲨烯,并且是固醇合成的第一步。角鲨烯合酶的特定抑制剂会抑制胆固醇的生物合成,但不会阻止类异戊二烯途径的其他产物(例如三氢乙醇和泛醌)的形成。 RPR 107393 [3-羟基-3- [4-(喹啉-6-基)苯基] -1-氮杂双环[2-2-2]辛烷二盐酸盐]及其R和S对映异构体是大鼠肝脏微粒体角鲨烯合酶的有效抑制剂,IC50值为0.6至0.9 nM。对大鼠口服后1小时,RPR 107393抑制了肝脏中[14C]甲羟戊酸从头开始的[14C]胆固醇生物合成,ED50值为5 mg / kg。在对这些动物的肝脏进行酸处理后,鉴定出[14C]法呢基焦磷酸的二酸代谢物。这些结果支持了证明这些化合物是角鲨烯合酶抑制剂的体外数据。在大鼠中,RPR 107393(每天两次,每日30 mg / kg,每天两次)可将血清总胆固醇降低<或= 51%。在相同的范例中,HMG-CoA还原酶抑制剂洛伐他汀未能降低大鼠的血清胆固醇。在mar猴中,RPR 107393(20 mg / kg b.i.d.)服用1周后血浆胆固醇浓度降低了50%;这大于用洛伐他汀或普伐他汀观察到的减少,当以50 mg / kg b.i.d服用1周时,两者均未使血浆胆固醇降低> 31%。 RPR 107393的R和S对映体(每天20 mg / kg,每天口服7天)分别降低血浆低密度脂蛋白胆固醇50%和43%,而高密度脂蛋白胆固醇不变。总之,RPR 107393是鲨烯合酶的有效抑制剂。它是大鼠​​和小猿口服有效的降胆固醇药,在小猿中具有比洛伐他汀或普伐他汀更大的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号